EXEL vs NBIX
Exelixis, Inc. (EXEL) and Neurocrine Biosciences Inc (NBIX) are both filed with the SEC under Biological Products, (No Diagnostic Substances). NBIX is 1.2× EXEL's size by market cap ($15.8B against $13.7B); NBIX trades at the higher fiscal-year P/E (33.4× against 31.4×); EXEL reports the higher net margin (33.7% against 16.7%); NBIX grew sales faster over three years (+24.3% against +12.9%); and over the past year EXEL returned +43.7% against NBIX's +10.9%.
| EXEL | NBIX | |
|---|---|---|
| Last close | $54.45 | $154.06 |
| Market cap | $13.7B | $15.8B |
| P/E (FY) | 31.4× | 33.4× |
| P/S | 5.9× | 5.5× |
| Operating margin | 37.6% | 21.6% |
| Net margin | 33.7% | 16.7% |
| Return on equity | 35.5% | 16.4% |
| Sales growth (3y) | +12.9% | +24.3% |
| EPS growth (3y) | +70.6% | +44.1% |
| 1-year return | +43.7% | +10.9% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: EXEL FY2026 (ended 2026-01-02); NBIX FY2025 (ended 2025-12-31).
Who holds them, and who has traded them
| EXEL | NBIX | |
|---|---|---|
| Institutional holders (13F) | 693 | 691 |
| Insider buyers − sellers (180d) | -5 | -5 |
| Congressional trades disclosed (180d) | 0 | 0 |
| Executive-branch officials on file — trades disclosed (180d) | 0 | 0 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
EXEL vs NBIX: common questions
- Is EXEL bigger than NBIX?
- NBIX carries the larger market cap — $15.8B against $13.7B, both struck on 2026-08-27.
- Which trades at a higher P/E, EXEL or NBIX?
- NBIX, at a fiscal-year 33.4× against 31.4× for EXEL. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have EXEL and NBIX performed over the past year?
- EXEL returned +43.7% and NBIX +10.9%, measured on the trailing calendar year to the last close.
- How many institutions hold EXEL and NBIX?
- 693 13F filers report a position in EXEL and 691 in NBIX, on the latest quarter in the panel.
- Are EXEL and NBIX in the same industry?
- Both are filed with the SEC under Biological Products, (No Diagnostic Substances), which is the classification this pairing is built on.
EXEL overview → · NBIX overview → · EXEL institutional ownership → · NBIX institutional ownership →
More in Biological Products, (No Diagnostic Substances): AMGN vs BIIB · AMGN vs EXEL · AMGN vs GILD · AMGN vs HALO
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/exel-vs-nbix